Search results for CD3

Odronextamab Biosimilar – Anti-CD3, CD20 mAb – Research Grade, ProteoGenix, PX-TA1599

Description of Odronextamab Biosimilar - Anti-CD3, CD20 mAb - Research Grade Introduction: Odronextamab is a biosimilar antibody that targets both CD3 and CD20, making it a promising therapeutic option for various diseases. In this article, we will delve into the structure, activity, and potential applications of this unique antibody. Structure of Odronextamab: Odronextamab is a bispecific antibody, meaning it has two binding sites that can recognize and bind to two different targets. It is composed of two monoclonal antibodies, one targeting CD3 and the other targeting CD20, linked together by a flexible linker. This structure allows for simultaneous binding to both CD3 and CD20, leading to a potent and targeted immune response. Activity of Odronextamab: Odronextamab has a dual mechanism of action, making it a highly effective therapeutic agent. By binding to CD3, it activates T cells and stimulates their proliferation, leading to a robust immune response. At the same time, by binding to CD20, it triggers the destruction of B cells, which are involved in various autoimmune and malignant diseases. This dual activity makes Odronextamab a versatile and potent therapeutic option. Applications of Odronextamab: 1. Treatment of Autoimmune Diseases: Autoimmune diseases occur when the immune system mistakenly attacks healthy cells and tissues. Odronextamab, with its dual activity, can effectively target both T and B cells involved in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus. By suppressing the overactive immune response, Odronextamab can help alleviate the symptoms and improve the quality of life for patients with these conditions. 2. Cancer Therapy: CD20 is a protein found on the surface of B cells, which are involved in the development of various types of cancer, including lymphoma and leukemia. By targeting CD20, Odronextamab can effectively destroy these cancerous B cells, leading to tumor regression and improved patient outcomes. Additionally, the activation of T cells by CD3 binding can also enhance the immune response against cancer cells, making Odronextamab a promising option for cancer therapy. 3. Transplant Rejection Prevention: One of the major challenges in organ transplantation is the risk of rejection by the recipient’s immune system. Odronextamab can be used as an immunosuppressant to prevent transplant rejection by targeting and suppressing T cell activity. This can increase the success rate of organ transplantation and improve patient outcomes. 4. Treatment of Hematological Disorders: Hematological disorders, such as certain types of anemia and thrombocytopenia, are characterized by abnormal levels of blood cells. Odronextamab can be used to target and destroy specific types of B cells involved in these disorders, leading to the restoration of normal blood cell levels. Conclusion: In summary, Odronextamab is a promising biosimilar antibody with a unique structure and dual activity against CD3 and CD20. Its potential applications in various diseases, including autoimmune disorders, cancer, transplant rejection, and hematological disorders, make it a versatile and potent therapeutic option. Further research and clinical trials are needed to fully explore the potential of Odronextamab in the treatment of these diseases.

CD3 (17A2) Rat Monoclonal Antibody (APC Conjugate)#24265, Cell Signaling Technology (CST), 24265

CD3 (17A2) Rat Monoclonal Antibody (APC Conjugate) recognizes endogenous levels of total CD3ε, CD3γ, and CD3δ proteins. This antibody conjugate detects epitopes within the extracellular domain.

CD3 (17A2) Rat Monoclonal Antibody (FITC Conjugate)#86603, Cell Signaling Technology (CST), 86603

CD3 (17A2) Rat Monoclonal Antibody (FITC Conjugate) recognizes endogenous levels of total CD3ε, CD3γ, and CD3δ proteins. This antibody conjugate detects epitopes within the extracellular domains.

CD3 (17A2) Rat Monoclonal Antibody (PE Conjugate)#28306, Cell Signaling Technology (CST), 28306

CD3 (17A2) Rat Monoclonal Antibody (PE Conjugate) recognizes endogenous levels of total CD3ε, CD3γ, and CD3δ proteins. This antibody conjugate detects epitopes within the extracellular domains.

MultiPro^® 5CFLX Anti-Human CD3 (OKT3), Proteintech, G65133-1-5C

G65133-1-5C targets CD3 in Single Cell (Intra) applications and shows reactivity with Human samples.

CD3 (17A2) Rat Monoclonal Antibody (redFluor 710 Conjugate)#26582, Cell Signaling Technology (CST), 26582

CD3 (17A2) Rat Monoclonal Antibody (redFluor 710 Conjugate) recognizes endogenous levels of total CD3ε, CD3γ, and CD3δ proteins. This antibody conjugate detects epitopes within the extracellular domains.

CD3 (17A2) Rat Monoclonal Antibody (violetFluor 450 Conjugate)#38527, Cell Signaling Technology (CST), 38527

CD3 (17A2) Rat Monoclonal Antibody (violetFluor 450 Conjugate) recognizes endogenous levels of total CD3ε, CD3γ, and CD3δ proteins. This antibody conjugate detects epitopes within the extracellular domains.

Immunotag^TMCD3 ζ (Phospho-Tyr142) Antibody, G-Biosciences, ITA1596

CD3 epsilon (D4V8L) Rabbit Monoclonal Antibody (BSA and Azide Free)#47359, Cell Signaling Technology (CST), 47359

CD3 epsilon (D4V8L) Rabbit Monoclonal Antibody (BSA and Azide Free) recognizes endogenous levels of total mouse CD3ε protein. Non-specific staining in mouse pancreas has been observed. This antibody may react weakly with human CD3ε, but is not suggested for use in immunohistochemical analysis of human tissues. Instead, CD3 epsilon (D7A6E^TM) Rabbit Monoclonal Antibody #85061 is recommended for IHC analysis of human tissue samples.

CD3 epsilon (E4T1B) Rabbit Monoclonal Antibody (BSA and Azide Free)#73484, Cell Signaling Technology (CST), 73484

CD3 epsilon (E4T1B) Rabbit Monoclonal Antibody (BSA and Azide Free) recognizes endogenous levels of total CD3ε protein.